2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dipeptidyl Peptidase
  5. Dipeptidyl Peptidase Inhibitor

Dipeptidyl Peptidase Inhibitor

Dipeptidyl Peptidase Isoform Comparison

Dipeptidyl Peptidase Inhibitors (156):

Cat. No. Product Name Effect Purity
  • HY-A0299A
    H-Gly-Pro-Hyp-OH acetate
    		Inhibitor
    H-Gly-Pro-Hyp-OH acetate is a dipeptidyl peptidase 4 (DPP-4) inhibitor with an IC50 value of 2.51 mM. H-Gly-Pro-Hyp-OH acetate is promising for research of diabetes.
  • HY-10284R
    Linagliptin (Standard)
    		Inhibitor
    Linagliptin (Standard) is the analytical standard of Linagliptin. This product is intended for research and analytical applications. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
  • HY-10285S2
    Saxagliptin-13C2
    		Inhibitor
    Saxagliptin-13C2 (BMS-477118-13C2) is 13C labeled Saxagliptin. Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research.
  • HY-A0023AR
    Alogliptin (Standard)
    		Inhibitor
    Alogliptin (Standard) is the analytical standard of Alogliptin. This product is intended for research and analytical applications. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes.
  • HY-N4069
    Lupinalbin A
    		Inhibitor
    Lupinalbin A (Boeravinone L) is a dipeptidyl peptidase 4 (DPP4) and α-glucosidase inhibitor with IC50 values ​​of 45.2 and 53.4 µM, respectively. Lupinalbin A exhibits antidiabetic activity.
  • HY-14291S
    Vildagliptin-d3
    		Inhibitor
    Vildagliptin-d3 is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].
  • HY-15981R
    Omarigliptin (Standard)
    		Inhibitor
    Omarigliptin (Standard) is the analytical standard of Omarigliptin. This product is intended for research and analytical applications. Omarigliptin (MK-3102) is a potent, selective, orally active and cross the blood-brain barrier dipeptidyl peptidase 4 (DPP-4) inhibitor. Omarigliptin shows anti-parkinsonian activity. Omarigliptin has the neuroprotective effect to improve diabetes-associated cognitive dysfunction.
  • HY-119266
    HTS13517
    		Inhibitor
    HTS13517 is a DPP4 inhibitor, with an IC50 of 10.73 μM.
  • HY-13749BR
    Sitagliptin (phosphate monohydrate) (Standard)
    		Inhibitor
    Sitagliptin (phosphate monohydrate) (Standard) is the analytical standard of Sitagliptin (phosphate monohydrate). This product is intended for research and analytical applications. Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-10285R
    Saxagliptin (Standard)
    		Inhibitor
    Saxagliptin (Standard) is the analytical standard of Saxagliptin. This product is intended for research and analytical applications. Saxagliptin (BMS-477118) is a potent, selective, reversible, competitive and orally active dipeptidyl peptidase-4 (DPP-4) (Ki = 0.6-1.3 nM) inhibitor. Saxagliptin has the peotential for type 2 diabetes mellitus research.
  • HY-109060
    Garvagliptin
    		Inhibitor
    Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect.
  • HY-10284S4
    Linagliptin-d5
    		Inhibitor
    Linagliptin-d5 (BI 1356-d5) is deuterium labeled Linagliptin. Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM.
  • HY-U00346A
    TS-021
    		Inhibitor
    TS-021 is a selective，orally active，reversible and long-acting DPP-IV inhibitor，and exhibits significant inhibition selectivity against DPP-8 (> 600 fold)，DPP-9 (> 1200 fold) and other peptidases (> 15,000 fold). TS-021 inhibits DPP-IV activity in human plasma with an IC50 value of 5.34 nM. TS-021 has long-term persistent plasma drug concentration and potent antihyperglycemic activity，and increases in the active form of GLP-1.
  • HY-14291S5
    Vildagliptin-d6
    		Inhibitor
    Vildagliptin-d6 (LAF237-d6 ) is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
  • HY-13749D
    (Rac)-Sitagliptin
    		Inhibitor
    (Rac)-Sitagliptin is an isoform of Sitagliptin (HY-13749), which is a potent and orally active inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-117985S
    Evogliptin-d9
    		Inhibitor
    Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.